Summaries of health policy coverage from major news organizations
GlaxoSmithKline Faces New Charges in Lawsuit Over AIDS Drugs
GlaxoSmithKline is facing new charges in an antitrust lawsuit challenging the lack of generic competition to its AIDS drugs Combivir and Trizivir, the Bloomberg News/Fort Lauderdale Sun-Sentinel reports. The AIDS Healthcare Foundation last week amended the lawsuit it filed in July in Los Angeles, claiming that the drug maker "lied" to the U.S. Patent and Trademark Office when it sought a patent on AZT, a "key ingredient" in both drugs. The lawsuit contends that Glaxo did not invent AZT and that it did not conduct the research demonstrating the drug's efficacy in fighting HIV, the Bloomberg News/Sun-Sentinel reports. Nancy Pekarek, a spokesperson for Glaxo, said the company "never claimed to have invented AZT," but rather "identified its use in the treatment of AIDS." Ged Kenslea, a spokesperson for the foundation, said that the group was focusing on AZT because it was the first AIDS drug, and it "set the pricing level for any drug that followed" (Decker, Bloomberg News/Fort Lauderdale Sun-Sentinel, 10/15).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.